IBIO Stock - iBio, Inc.
Unlock GoAI Insights for IBIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $400,000 | $225,000 | N/A | $1.88M | $2.37M |
| Gross Profit | $400,000 | $225,000 | N/A | $-1,907,000 | $909,000 |
| Gross Margin | 100.0% | 100.0% | N/A | -101.2% | 38.3% |
| Operating Income | $-18,602,000 | $-16,634,000 | $-29,343,000 | $-29,697,000 | $-31,111,000 |
| Net Income | $-18,377,000 | $-24,907,000 | $-65,010,000 | $-50,391,000 | $-23,207,000 |
| Net Margin | -4594.3% | -11069.8% | N/A | -2674.7% | -978.8% |
| EPS | $-1.75 | $-6.50 | $-23.94 | $-58.49 | $-60.00 |
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 21st 2025 | Oppenheimer | Initiation | Outperform | $5 |
| October 17th 2025 | Leerink Partners | Initiation | Outperform | $2 |
| May 28th 2024 | Chardan Capital Markets | Initiation | Buy | $5 |
Earnings History & Surprises
IBIOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 30, 2026 | — | — | — | — |
Q1 2026 | Feb 9, 2026 | $-0.10 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.07 | $-0.11 | -57.1% | ✗ MISS |
Q3 2025 | Sep 5, 2025 | $-0.39 | $-0.31 | +20.5% | ✓ BEAT |
Q2 2025 | May 2, 2025 | $-0.39 | $-0.49 | -25.6% | ✗ MISS |
Q1 2025 | Feb 10, 2025 | $-0.45 | $-0.48 | -6.7% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.46 | $-0.46 | 0.0% | = MET |
Q3 2024 | Sep 25, 2024 | $-0.47 | $-0.91 | -93.6% | ✗ MISS |
Q2 2024 | May 13, 2024 | — | $-0.71 | — | — |
Q1 2024 | Feb 9, 2024 | — | $-2.42 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-4.20 | — | — |
Q3 2023 | Sep 27, 2023 | $-0.41 | $0.26 | +163.4% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-3.42 | $-6.61 | -93.4% | ✗ MISS |
Q1 2023 | Feb 14, 2023 | $-146.90 | $-21.60 | +85.3% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-1.85 | $-2.05 | -10.8% | ✗ MISS |
Q4 2022 | Oct 11, 2022 | $-2.12 | $-1.96 | +7.5% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-1.25 | $-30.00 | -2300.0% | ✗ MISS |
Q1 2022 | Feb 14, 2022 | $-1.00 | $-25.00 | -2400.0% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-1.25 | $-20.00 | -1500.0% | ✗ MISS |
Q3 2021 | Sep 27, 2021 | — | $-25.00 | — | — |
Latest News
EcoR1 Capital Reports 9.9% Passive Stake In IBio As Of Dec 10
📈 PositiveiBio Q1 EPS $(0.11) Misses $(0.10) Estimate, Sales $100.000K Beat $25.000K Estimate
📈 PositiveiBio Announces New Preclinical Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate Supported By Preclinical Data
📈 PositiveiBio shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $5 price target.
📈 PositiveOppenheimer Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $5
📈 PositiveLeerink Partners Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $2
📈 PositiveiBio Says Revenues For The Fiscal Year Ended June 30, 2025, Were Approximately $0.4M, An Increase Of $0.2M Over Fiscal Year 2024.
📈 PositiveiBio Prices Public Offering For Gross Proceeds Of ~$50M
➖ NeutraliBio drops on proposed public offering
📉 NegativeIBio shares are trading lower after the company announced a proposed public offering.
📉 NegativeiBio Announces Proposed Public Offering; Size Not Disclosed
➖ NeutralFrequently Asked Questions about IBIO
What is IBIO's current stock price?
What is the analyst price target for IBIO?
What sector is iBio, Inc. in?
What is IBIO's market cap?
Does IBIO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IBIO for comparison